stockrowHarmony Biosciences Holdings, Inc.
HRMY Healthcare Biotechnology
Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024.
- Revenue
- +12.3%
- EPS
- −6.24%
- Free cash flow
- −29.4%
- Total debt
- −11.5%
Quarter to September 2026, against a year earlier
Follow HRMY
Alert me
Harmony Biosciences Holdings, Inc. (HRMY) EV/EBITDA
As of 6 November 2026, Harmony Biosciences Holdings, Inc. (HRMY) trades at a EV/EBITDA of 5.4×. Over the past ten years it has ranged from 0.0× (December 2020) to 34.4× (June 2021); the current reading is higher than 11% of that period. That is above the Biotechnology industry median of 0.7× and below the Healthcare sector median of 8.5×.
EV/EBITDA, daily
Embed this chart
Annual newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| FY2025 | 6.6× | (15.52%) |
| FY2024 | 7.8× | 1.10% |
| FY2023 | 7.7× | (62.68%) |
| FY2022 | 20.7× | (6.59%) |
| FY2021 | 22.2× | (26.69%) |
| FY2020 | 30.3× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| Sep 2026 | 6.9× | 9.76% |
| Jun 2026 | 6.2× | 17.67% |
| Mar 2026 | 5.3× | (19.67%) |
| Dec 2025 | 6.6× | 51.77% |
| 23 more quarters | Free account |
Against its own ten years
EV/EBITDA against peers
| Company | EV/EBITDA |
|---|---|
| TRVI Trevi Therapeutics, Inc. compare | n/m |
| MESO Mesoblast Limited compare | n/m |
| MAZE Maze Therapeutics, Inc. compare | n/m |
| VIR Vir Biotechnology, Inc. compare | n/m |
| TRAX First Tracks Biotherapeutics, Inc. compare | n/m |
| REPL Replimune Group, Inc. compare | n/m |
| SRPT Sarepta Therapeutics, Inc. compare | n/m |
| HRMY Harmony Biosciences Holdings, Inc. | 5.4× |
| FTRE Fortrea Holdings Inc. compare | 32.1× |
| Biotechnology industry median | 0.7× |
| Healthcare sector median | 8.5× |
| Market median | 10.9× |
What EV/EBITDA is
Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)